Palvella Therapeutics (PVLA) Share-based Compensation (2015 - 2026)
Palvella Therapeutics (PVLA) reported Share-based Compensation of $3.4 million for Q1 2026, up 208.59% year-over-year from $1.1 million in Q1 2025, and up 62.0% on a QoQ basis from $2.1 million in Q4 2025.
Palvella Therapeutics (PVLA) has 12 years of Share-based Compensation data on file, last reported at $3.4 million in Q1 2026.
- Quarterly Share-based Compensation rose 208.59% year-over-year to $3.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.7 million (up 388.36% YoY) and the FY2025 annual result came in at $6.4 million, up 671.2% from the prior year.
- Share-based Compensation advanced to $3.4 million in Q1 2026 per PVLA's latest filing, from $2.1 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $3.4 million in Q1 2026 and bottomed at -$2.3 million in Q4 2023.
- The 5-year median for Share-based Compensation is $974000.0 (2022), against an average of $918352.9.
- The widest annual swing landed in 2023, when Share-based Compensation tumbled 341.83%; it then surged 799.5% in 2025.
- Tracing PVLA's Share-based Compensation over 5 years: stood at $949000.0 in 2022, then plunged by 341.83% to -$2.3 million in 2023, then surged by 111.68% to $268000.0 in 2024, then soared by 677.61% to $2.1 million in 2025, then jumped by 62.0% to $3.4 million in 2026.
- Per Business Quant, the three latest PVLA Share-based Compensation figures stand at $3.4 million (Q1 2026), $2.1 million (Q4 2025), and $1.8 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 892,057.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 305,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 166.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 257.40 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 70.15 Mn |
| 10 | Palvella Therapeutics | 1.47 Bn | 1.21 Bn | - | 3.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.38 Mn |
| Mar 31, 2026 | 3.38 Mn |
| Dec 31, 2025 | 2.08 Mn |
| Dec 31, 2025 | 2.08 Mn |
| Sep 30, 2025 | 1.79 Mn |
| Sep 30, 2025 | 1.79 Mn |
| Jun 30, 2025 | 1.43 Mn |
| Jun 30, 2025 | 1.43 Mn |
| Mar 31, 2025 | 1.09 Mn |
| Mar 31, 2025 | 1.09 Mn |
| Dec 31, 2024 | 268,000.00 |
| Dec 31, 2024 | 268,000.00 |
| Sep 30, 2024 | 199,000.00 |
| Sep 30, 2024 | 199,000.00 |
| Jun 30, 2024 | 217,000.00 |
| Jun 30, 2024 | 217,000.00 |
| Mar 31, 2024 | 146,000.00 |
| Mar 31, 2024 | 146,000.00 |
| Dec 31, 2023 | -2.30 Mn |
| Dec 31, 2023 | -2.30 Mn |
| Sep 30, 2023 | 966,000.00 |
| Sep 30, 2023 | 966,000.00 |
| Jun 30, 2023 | 1.05 Mn |
| Jun 30, 2023 | 1.05 Mn |
| Mar 31, 2023 | 884,000.00 |
| Mar 31, 2023 | 884,000.00 |
| Dec 31, 2022 | 949,000.00 |
| Dec 31, 2022 | 949,000.00 |
| Sep 30, 2022 | 974,000.00 |
| Sep 30, 2022 | 974,000.00 |
| Jun 30, 2022 | 1.30 Mn |
| Jun 30, 2022 | 1.30 Mn |
| Mar 31, 2022 | 1.18 Mn |
| Mar 31, 2022 | 1.18 Mn |
| Dec 31, 2021 | 1.32 Mn |
| Dec 31, 2021 | 1.32 Mn |
| Sep 30, 2021 | 1.37 Mn |
| Sep 30, 2021 | 1.37 Mn |
| Jun 30, 2021 | 1.33 Mn |
| Jun 30, 2021 | 1.33 Mn |
| Mar 31, 2021 | 1.20 Mn |
| Mar 31, 2021 | 1.20 Mn |
| Dec 31, 2020 | 1.17 Mn |
| Dec 31, 2020 | 1.17 Mn |
| Sep 30, 2020 | 1.40 Mn |
| Sep 30, 2020 | 1.40 Mn |
| Jun 30, 2020 | 1.24 Mn |
| Jun 30, 2020 | 1.24 Mn |
| Mar 31, 2020 | 1.28 Mn |
| Mar 31, 2020 | 1.28 Mn |
| Dec 31, 2019 | 1.11 Mn |
| Dec 31, 2019 | 1.11 Mn |
| Sep 30, 2019 | 1.52 Mn |
| Sep 30, 2019 | 1.52 Mn |
| Jun 30, 2019 | 1.45 Mn |
| Jun 30, 2019 | 1.45 Mn |
| Mar 31, 2019 | 1.29 Mn |
| Mar 31, 2019 | 1.29 Mn |
| Dec 31, 2018 | 1.28 Mn |
| Dec 31, 2018 | 1.28 Mn |
| Sep 30, 2018 | 1.31 Mn |
| Sep 30, 2018 | 1.31 Mn |
| Jun 30, 2018 | 1.35 Mn |
| Jun 30, 2018 | 1.35 Mn |
| Mar 31, 2018 | 1.00 Mn |
| Mar 31, 2018 | 1.00 Mn |
| Dec 31, 2017 | 1.08 Mn |
| Dec 31, 2017 | 1.08 Mn |
| Sep 30, 2017 | 649,948.00 |
| Sep 30, 2017 | 649,948.00 |
| Jun 30, 2017 | 559,878.00 |
| Jun 30, 2017 | 559,878.00 |
| Mar 31, 2017 | 752,000.00 |
| Mar 31, 2017 | 752,000.00 |
| Dec 31, 2016 | 478,659.00 |
| Dec 31, 2016 | 478,659.00 |
| Sep 30, 2016 | 446,113.00 |
| Sep 30, 2016 | 446,113.00 |
| Jun 30, 2016 | 611,845.00 |
| Jun 30, 2016 | 611,845.00 |
| Mar 31, 2016 | 368,383.00 |
| Mar 31, 2016 | 368,383.00 |
| Dec 31, 2015 | -376,764.00 |
| Dec 31, 2015 | -376,764.00 |
| Sep 30, 2015 | 337,789.00 |
| Sep 30, 2015 | 337,789.00 |
| Jun 30, 2015 | 268,039.00 |
| Jun 30, 2015 | 268,039.00 |
| Mar 31, 2015 | 311,066.00 |
| Mar 31, 2015 | 311,066.00 |